How did the Cochlear (ASX:COH) share price respond last earnings season?

Shares in the hearing aid manufacturer are on the move in anticipation of its FY21 earnings tomorrow

| More on:
An older woman tries to listen by cupping her ear.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price has stepped into the green in afternoon trade on Thursday.

Shares in the hearing aid manufacturer are exchanging hands at $257.12 apiece, a 1.23% jump from yesterday's close of $253.

The Cochlear share price is on the move as the company is due to report its FY21 earnings on Friday.

In addition, given its strength on the charts this year to date, it's worthwhile investigating what happened to the Cochlear share price after the company's last earnings report. Let's do just that.

What did Cochlear deliver back in February?

The company recognised a 4% decline in first-half sales to $742 million. This carried through to a 6% decline in underlying net profit, to $125 million.

Moreover, the company saw a recovery in its key markets, including the US, Japan, Korea, and China. Furthermore, Cochlear sales were strong in Europe in the first half.

In addition, Cochlear declared a $1.15 per share dividend, which was a 28% down-step from the year prior.

Given this momentum, Cochlear provided full-year net profit guidance of $225 million to $245 million, calling for a 46% to 59% year-on-year increase, respectively.

What happened to the Cochlear share price?

In a negative for the Cochlear share price, investors punished the company on the charts in the two weeks following the release. It was trading at $221 per share at the close on 19 February.

It appeared the market received a decline in sales and net profit with closed arms. What's more, the dividend haircut didn't go down too well, either.

As a result, the Cochlear share price immediately took a hit, wiping $21 per share or 9.5% off the charts.

However, in a demonstration of resiliency, Cochlear shares have since climbed back north at a tremendous pace.

To illustrate, since the low quoted above of $200 on 5 May, Cochlear has gained $57 per share, or a further 28.5%.

Given there's been no market-sensitive information for the company since that time, it may be that investors are baking in the 46% – 59% in growth profit guidance for FY22 that management alluded to back in February.

Nonetheless, Cochlear shareholders will be hoping the company delivers on its guidance targets. Especially considering how the market reacted to its previous earnings report.

At the current price, Cochlear has a market capitalisation of $16.7 billion, and has climbed 35% since January 1.

For context, the S&P/ASX 200 index (ASX: XJO) has posted a return of around 14% this year to date.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »